{"gene":"GRIA3","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2025,"finding":"Cryo-EM structures of Ca2+-permeable GluA3 homomers reveal a unique architecture where the N-terminal domain (NTD) and ligand-binding domain (LBD) tiers are closely coupled throughout gating states. A stacking interaction between two Arg163 residues in the NTD dimer interface traps a unique NTD dimer conformation enabling close NTD-LBD contacts. Rupture of the Arg163 stack alters extracellular region structure/dynamics and increases GluA3 heteromer trafficking to synapses. A mammalian-specific GluA3 trafficking checkpoint determines LBD tier conformational stability.","method":"Cryo-electron microscopy with functional validation (mutagenesis, trafficking assays)","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structures across gating states combined with mutagenesis and functional trafficking validation in a single rigorous study","pmids":["40592473"],"is_preprint":false},{"year":2017,"finding":"GluA2/3-containing AMPARs are in a low-conductance state under basal conditions and contribute little to synaptic currents despite being present at synapses. When intracellular cAMP levels rise (e.g., via β-adrenergic receptor activation), GluA2/3 channels shift to a high-conductance state, producing synaptic potentiation. This cAMP-driven potentiation requires both PKA and the GTPase Ras activation.","method":"Electrophysiology in mouse hippocampal neurons (CA1), pharmacological manipulation of cAMP/PKA/Ras pathways, GluA3 knockout comparison","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (electrophysiology, pharmacology, genetic KO) in mouse neurons, replicated across multiple experimental conditions in one rigorous study","pmids":["28762944"],"is_preprint":false},{"year":2017,"finding":"Cerebellar LTP at the parallel-fiber-to-Purkinje-cell synapse and vestibulo-ocular reflex adaptation depend on GluA3-containing AMPARs, not GluA1-containing AMPARs. This LTP does not require GluA1 AMPAR trafficking but instead requires changes in open-channel probability of GluA3-AMPARs mediated by cAMP signaling and Epac activation.","method":"GluA3 and GluA1 knockout mice, electrophysiology, VOR behavioral assay, pharmacological cAMP/Epac manipulation","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with KO mice, electrophysiology, and behavioral assays across multiple orthogonal methods in one study","pmids":["28103481"],"is_preprint":false},{"year":2016,"finding":"Aβ oligomer-mediated synaptic depression, spine loss, and blockade of LTP all require the presence of GluA3-containing AMPARs. Hippocampal neurons lacking GluA3 are resistant to Aβ-mediated synaptic depression and spine loss. Aβ-overproducing mice show memory impairment that is absent in GluA3-deficient congenics.","method":"GluA3 knockout mice crossed with Aβ-overproducing AD mouse model; electrophysiology, spine imaging, behavioral memory tests","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with KO and transgenic mice, multiple phenotypic readouts (electrophysiology, imaging, behavior), replicated across multiple experimental paradigms","pmids":["27708157"],"is_preprint":false},{"year":2025,"finding":"Aβ oligomers trigger endocytosis of GluA3-containing AMPARs and promote their translocation to endolysosomal compartments for degradation. These effects critically depend on the PDZ-binding motif of GluA3; a single point mutation in the GluA3 PDZ-binding motif prevents Aβ-driven endocytosis and renders synapses fully resistant to Aβ. Proteomics of APP/PS1 transgenic mouse synaptosomes confirmed selective early reduction of GluA3.","method":"Electrophysiology, AMPAR imaging, site-directed mutagenesis of PDZ-binding motif, live-cell endocytosis assays, synaptosome proteomics from APP/PS1 mice","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis identifying specific motif, imaging of endocytosis/trafficking, proteomics, electrophysiology — multiple orthogonal methods in one study","pmids":["39779375"],"is_preprint":false},{"year":2010,"finding":"Single-channel analysis of homomeric GluA3 receptors shows activation by glutamate and the partial agonist fluorowillardiine to the same three open conductance levels but with different open probabilities. Five modes of channel activity were identified, analyzable with a kinetic model of three closed states and two open states per conductance level.","method":"Single-channel electrophysiology (patch clamp) with agonist concentration series and X-means algorithm sorting","journal":"Biophysical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous single-channel recordings with multiple agonists and kinetic modeling, single lab","pmids":["20816055"],"is_preprint":false},{"year":2010,"finding":"Crystal structures of the flop-selective allosteric modulator PEPA bound to the ligand-binding domains of GluA2 and GluA3 flop isoforms reveal that flop selectivity is conferred by bidentate hydrogen bonding between PEPA and N754 (asparagine in flop; serine in flip). Five subsites on the binding surface contribute to stoichiometry, orientation, and functional outcome of modulator binding.","method":"X-ray crystallography of GluA2 and GluA3 LBD-PEPA complexes","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures of both GluA2 and GluA3 with the modulator, specific hydrogen-bonding contacts identified, single lab","pmids":["20199107"],"is_preprint":false},{"year":2018,"finding":"Druggability simulations identified a novel ligand-binding site specific to the GluA3 AMPAR N-terminal domain (NTD), arising from its unique conformational flexibility. Crystal structures of GluA3 NTD were trapped in vastly different conformational states, revealing pharmacophoric features not present in other AMPAR subunits.","method":"Molecular dynamics druggability simulations plus X-ray crystallography of GluA3 NTD in multiple conformations","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures combined with computational simulations, novel site experimentally confirmed, single lab","pmids":["30528594"],"is_preprint":false},{"year":2016,"finding":"Poor surface expression of homomeric GluA3 receptors is caused by nonproductive assembly and aggregation, driven by residues Tyr-454 and Arg-461 in the ligand-binding domain. Co-assembly with GluA2 (but not stargazin) rescues surface expression. GluA3 homomers show a Tyr-454/Arg-461-dependent tendency to aggregate detectable by detergent solubility and density-gradient centrifugation.","method":"Biochemical fractionation (nonionic detergent solubility, density gradient centrifugation, native gel electrophoresis), surface expression assays, site-directed mutagenesis of LBD residues","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis identifying specific residues, multiple orthogonal biochemical methods, single lab","pmids":["26912664"],"is_preprint":false},{"year":2017,"finding":"ABHD6 suppresses membrane delivery and glutamate-induced currents of GluA2- and GluA3-containing AMPA receptors. Pull-down experiments show ABHD6 binds directly to GluA1-3 via their C-terminal domains; deletion of the GluA C-terminus abolishes both ABHD6 binding and its inhibitory effects on surface expression and currents.","method":"HEK293T overexpression, electrophysiology, surface biotinylation assays, pull-down (ABHD6 binding to GluA C-termini), C-terminal deletion constructs","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pulldown and functional assays with deletion constructs, single lab, multiple methods","pmids":["28303090"],"is_preprint":false},{"year":2022,"finding":"Interaction proteomics on hippocampi from wildtype vs. Gria3 knockout mice shows that GluA2/3-containing AMPARs preferentially co-purify CNIH-2, TARP-γ2, and Noelin1 (Olfactomedin-1), whereas GluA1/2 receptors preferentially co-purify TARP-γ8, SynDIG4, and CNIH-2. TARP-γ8 and SynDIG4 interact directly and co-assemble into an AMPAR subcomplex at synaptic sites.","method":"Affinity purification mass spectrometry (interaction proteomics) from Gria1- or Gria3-KO mouse hippocampi; co-immunoprecipitation and fractionation for TARP-γ8/SynDIG4 interaction","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry interactome with KO controls plus orthogonal co-IP, single lab","pmids":["36429079"],"is_preprint":false},{"year":2017,"finding":"In cochlear nucleus, GluA3 subunits are concentrated at the center of auditory nerve-bushy cell (AN-BC) synapses at higher density than GluA4, whereas GluA4 is more abundant at AN-fusiform cell synapses. In GluA3-knockout mice, the central intrasynaptic distribution of AMPARs is lost and gold particles distribute evenly, demonstrating GluA3 specifically organizes the central clustering of AMPARs at AN-BC synapses.","method":"Quantitative freeze-fracture replica immunogold labeling (FRIL) of cochlear nucleus synapses in wildtype and GluA3-KO mice","journal":"Brain structure & function","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — quantitative ultrastructural immunogold localization with KO controls, rigorous single-synapse resolution, single lab","pmids":["28397107"],"is_preprint":false},{"year":2020,"finding":"GluA3 determines the ultrafast kinetics of endbulb-bushy cell synapse glutamatergic currents by promoting insertion of postsynaptic AMPARs containing fast-desensitizing flop subunits. GluA3 is also required for normal presynaptic terminal function, structure, and development: GluA3 KO mice show altered short-term depression, increased vesicle release probability, impaired vesicle replenishment, and reduced readily-releasable pool. GluA3 makes the speed of synaptic depression rate-invariant.","method":"Patch-clamp electrophysiology at endbulb synapses in wildtype vs. GluA3 KO mice, electron microscopy of presynaptic terminals","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — electrophysiology with KO genetic model combined with ultrastructural analysis, multiple phenotypic readouts","pmids":["32051325"],"is_preprint":false},{"year":2016,"finding":"Deletion of GluA3 leads to impaired auditory signaling (decreased ABR peak amplitudes, increased peak 2 latency, early hearing loss), reduced number and size of postsynaptic densities at AN-BC synapses, and hampered ABR threshold recovery after transient ear plugging, demonstrating GluA3 is required for normal auditory processing and experience-dependent synaptic plasticity.","method":"Auditory brainstem responses (ABR) and electron microscopy of AN-BC synapses in wildtype vs. GluA3-KO mice, with transient monaural earplugging paradigm","journal":"Hearing research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO genetic model with electrophysiological and ultrastructural readouts, single lab","pmids":["28011083"],"is_preprint":false},{"year":2017,"finding":"A missense variant A653T in the GRIA3 ion conduction pore (transmembrane domain) stabilizes the channel in a closed conformation in vitro, opposite to the Lurcher mutation effect. Knock-in of the orthologous mutation in mice by CRISPR-Cas9 causes significantly altered sleep/activity structure with fewer brief bouts and enhanced period lengthening under constant light.","method":"In vitro electrophysiology of A653T mutant channels; CRISPR-Cas9 knock-in mouse model with actigraphy/sleep analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro channel characterization plus knock-in mouse phenotyping, two orthogonal experimental approaches, single lab","pmids":["29016847"],"is_preprint":false},{"year":2021,"finding":"A gain-of-function variant R660T in GRIA3 causes slower desensitization and deactivation kinetics with substantial non-desensitized steady-state currents in homomeric GluA3 and in GluA2/GluA3 heteromers expressed in HEK cells. In cultured cerebellar granule neurons and hippocampal CA1 neurons expressing R660T, mEPSCs and evoked EPSCs are significantly slower than wildtype.","method":"Two-electrode voltage clamp in Xenopus oocytes, patch clamp in HEK cells and primary neurons, in utero electroporation into hippocampal CA1 neurons","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple expression systems and neuronal recordings, single lab but multiple orthogonal methods","pmids":["34161333"],"is_preprint":false},{"year":2024,"finding":"Electrophysiological assays of 43 GRIA3 missense variants found in NDD patients showed 31 alter receptor function: some are loss-of-function (reduced currents) and some are gain-of-function (increased/prolonged currents). GOF variants associate with earlier seizure onset, hypertonia, and movement disorders; LOF variants associate with later seizure onset, hypotonia, and sleep disturbances, establishing distinct NDD phenotypes for each functional class.","method":"Electrophysiological assays (patch clamp/voltage clamp) of 44 variants expressed in heterologous cells; clinical correlation across 25 patients","journal":"Brain","confidence":"High","confidence_rationale":"Tier 1 / Strong — large-scale systematic in vitro functional testing of 44 variants with clinical correlation, comprehensive coverage across multiple labs","pmids":["38038360"],"is_preprint":false},{"year":2020,"finding":"The GRIA3 missense variant Gly826Asp (c.2477G>A) in transmembrane domain 4 causes decreased current response to agonists (kainic acid and glutamate) and reduced cell-surface expression, consistent with a loss-of-function mechanism, as shown by two-electrode voltage clamp in Xenopus oocytes and a β-lactamase reporter assay in HEK293 cells.","method":"Two-electrode voltage clamp in Xenopus laevis oocytes; β-lactamase reporter assay in HEK293 cells for surface expression","journal":"Movement disorders","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro functional assays with two orthogonal methods, single lab","pmids":["32369665"],"is_preprint":false},{"year":2022,"finding":"Two GRIA3 missense variants, G630R and E787G, found in male patients with aggressive behavior, completely abolish GluA3 ion channel function. In GluA3 KO mice, excitatory neurotransmission and neuronal activity in the medial prefrontal cortex (mPFC) are impaired, and viral re-expression of GluA3 in the mPFC alleviates aggressive behavior.","method":"Patch-clamp electrophysiology of mutant channels in heterologous cells; GluA3 KO mice with viral rescue (AAV-mediated GluA3 re-expression in mPFC); aggression behavioral assays","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO with viral rescue establishing circuit-level mechanism, electrophysiology of mutant channels, multiple orthogonal methods, single lab","pmids":["35697757"],"is_preprint":false},{"year":2022,"finding":"A gain-of-function GRIA3 variant (p.Ala615Val) causes slower desensitization and deactivation kinetics in patch-clamp recordings. In a Drosophila model, expression of a double mutant (Ala615Val + Lurcher, which makes channels leaky) caused developmental defects, while either single variant alone did not, confirming partial GOF. The patient's seizures and hypertonia were ameliorated by carbamazepine, which inhibits glutamate release from presynapses.","method":"Patch-clamp recordings of mutant GluA3 in heterologous cells; Drosophila genetic model with epistasis; clinical pharmacological intervention","journal":"Human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro electrophysiology plus Drosophila epistasis, single lab, limited replication","pmids":["35031858"],"is_preprint":false},{"year":2025,"finding":"α2δ-1 (but not α2δ-2 or α2δ-3) co-expression diminishes GluA3 AMPAR currents and protein levels via ubiquitin-proteasome-mediated degradation. K861 at the GluA3 C-terminus is identified as a key ubiquitination site. Nerve injury increases GluA3 ubiquitination and reduces GluA3 and GluA2/GluA3 heteromer levels in spinal cord. Intrathecal Gria3 gene delivery reverses nerve injury-induced nociceptive hypersensitivity and restores GluA2/GluA3 heteromers.","method":"Co-expression in heterologous cells, proteasome inhibition, ubiquitination assays, site-directed mutagenesis of K861, nerve injury mouse model with intrathecal Gria3 gene delivery, electrophysiology","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis identifying ubiquitination site, proteasome inhibition, in vivo nerve injury model with gene therapy rescue, multiple orthogonal methods","pmids":["41129242"],"is_preprint":false},{"year":2010,"finding":"GRIA3 is a downstream transcriptional target of CUX1 in pancreatic cancer cells. Knockdown of GRIA3 reduces proliferation and migration and enhances apoptosis; overexpression has the opposite effects. GRIA3 knockdown reduces xenograft tumor growth in vivo. AMPAR antagonists (GYKI52466, SYM2206) decrease pancreatic cancer cell survival.","method":"RNAi loss-of-function screen, GRIA3 overexpression/knockdown in vitro, xenograft mouse model, AMPAR antagonist treatment","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi and overexpression with in vivo xenograft validation, single lab, pathway placement as CUX1 downstream target","pmids":["20689760"],"is_preprint":false},{"year":2019,"finding":"Anti-GluA3 autoantibodies in FTD patients decrease glutamate release and alter levels of GluA3-containing AMPAR, accompanied by changes in scaffolding proteins involved in receptor synaptic retention/internalization, as shown in FTD patient brain specimens and confirmed by TMS measures of glutamatergic neurotransmission.","method":"Molecular/neurochemical analyses on patient brain specimens (FTLD-tau neuropathology); transcranial magnetic stimulation; CSF glutamate/serine measurements","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient tissue neurochemistry with TMS functional validation, single lab, multiple methods","pmids":["31784278"],"is_preprint":false},{"year":2017,"finding":"CSF containing anti-GluA3 antibodies from FTD patients decreases GluA3 subunit synaptic localization of AMPARs and causes loss of dendritic spines in rat hippocampal primary cultures and hiPSC-derived neurons. Reduced GluA3 in the postsynaptic fraction is accompanied by increased neuronal Tau levels.","method":"Rat hippocampal primary neuronal cultures and hiPSC-derived neurons incubated with patient CSF; immunofluorescence for GluA3 synaptic localization; dendritic spine counting","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based functional antibody experiments with two neuronal models, single lab","pmids":["28751743"],"is_preprint":false},{"year":2025,"finding":"Long-term exposure to human anti-GluA3 IgGs causes delocalization of GluA3-containing AMPARs to extrasynaptic sites, dendritic arbor reorganization, increased dendritic spine number with altered morphology, enhancement of NMDA receptor-mediated postsynaptic Ca2+ currents, and increased nuclear phospho-CREB levels in primary rat hippocampal neurons.","method":"Primary rat hippocampal neurons, immunofluorescence for GluA3 localization, dendritic morphology analysis, Ca2+ imaging, phospho-CREB immunostaining","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based functional antibody experiments with multiple readouts, single lab","pmids":["39954743"],"is_preprint":false},{"year":2011,"finding":"After 7 days of monaural conductive hearing loss (earplugging), immunolabeling for GluA2/3 (but not GluA2 alone) increases on bushy cells and fusiform cells of both ipsilateral and contralateral cochlear nuclei, while GlyRα1 is downregulated in the same cells, indicating activity-dependent regulation of GluA3-containing AMPAR composition at auditory synapses.","method":"Monaural earplugging in rats, quantitative immunohistochemistry and biochemistry with subunit-specific antibodies","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative IHC with subunit-selective antibodies and functional hearing manipulation, single lab","pmids":["22044924"],"is_preprint":false},{"year":2024,"finding":"Loss-of-function of Gria3 in mice profoundly alters synapse protein composition, and transcriptomic analysis shows activity-regulated genes are downregulated in cortical regions while immune/glia-related pathways show brain-region-specific changes, distinct from Grin2a mutant mice despite both encoding glutamate receptor subunits associated with schizophrenia risk.","method":"Gria3 protein-truncating knock-in mouse model; transcriptomics (RNA-seq); synaptosome proteomics","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptomics and proteomics from genetic mouse model, preprint not peer-reviewed","pmids":[],"is_preprint":true},{"year":2024,"finding":"ABHD6 accelerates the deactivation and desensitization of GluA2(R)/GluA3(R) heteromeric receptors in the presence of TARP γ-2 (but not in its absence), as shown by ultra-fast glutamate application and outside-out patch recordings.","method":"Ultra-fast agonist application, outside-out patch recordings in HEK cells expressing GluA2/GluA3 heteromers with/without TARP γ-2 and ABHD6; ABHD6-KO neurons","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro kinetics recordings with KO neurons, preprint not peer-reviewed, single lab","pmids":[],"is_preprint":true}],"current_model":"GluA3 (GRIA3) is an AMPA-type glutamate receptor subunit that assembles primarily as GluA2/3 heteromers at cortical/hippocampal synapses and as Ca2+-permeable GluA3 homomers at sensory (auditory) synapses; cryo-EM structures reveal a unique NTD-LBD coupled architecture stabilized by an Arg163 stacking interaction that controls trafficking and gating. Under basal conditions GluA2/3 receptors are in a low-conductance state, but cAMP/PKA/Ras/Epac signaling shifts them to high conductance, enabling a distinct form of synaptic potentiation underlying hippocampal and cerebellar motor learning. Aβ oligomers drive endocytosis and lysosomal degradation of GluA3 via its PDZ-binding motif, causing synaptic depression; ABHD6 binds GluA3 C-termini to inhibit surface delivery; and α2δ-1 promotes K861-ubiquitination and proteasomal degradation of GluA3 to shift spinal AMPAR composition toward Ca2+-permeable homotetramers during neuropathic pain. Loss-of-function and gain-of-function GRIA3 variants each produce distinct neurodevelopmental encephalopathy phenotypes, and autoantibodies against GluA3 delocalize the receptor from synapses causing glutamatergic dysfunction in frontotemporal dementia."},"narrative":{"mechanistic_narrative":"GRIA3 encodes GluA3, an AMPA-type glutamate receptor subunit that mediates fast excitatory synaptic transmission and assembles into both Ca2+-permeable homomers and GluA2/3 heteromers at central and sensory synapses [PMID:28762944, PMID:28397107]. Its extracellular architecture is distinctive: cryo-EM of Ca2+-permeable GluA3 homomers reveals tightly coupled NTD and LBD tiers stabilized by an Arg163 stacking interaction whose rupture remodels the extracellular region and increases heteromer trafficking to synapses, defining a mammalian-specific trafficking checkpoint [PMID:40592473], while the NTD adopts a uniquely flexible set of conformations [PMID:30528594]. GluA3 homomers traffic poorly because Tyr-454/Arg-461 in the LBD drive nonproductive assembly and aggregation, a defect rescued by co-assembly with GluA2 [PMID:26912664]. Functionally, GluA2/3 receptors rest in a low-conductance state and convert to high conductance through cAMP/PKA/Ras and Epac signaling, generating a gating-based form of potentiation that underlies hippocampal and cerebellar parallel-fiber LTP and vestibulo-ocular reflex adaptation independently of GluA1 trafficking [PMID:28762944, PMID:28103481]. At auditory nerve-bushy cell synapses GluA3 organizes central AMPAR clustering, promotes fast-desensitizing flop-containing receptors that confer ultrafast, rate-invariant kinetics, and is required for normal presynaptic function and auditory processing [PMID:28397107, PMID:32051325, PMID:28011083]. GluA3 surface delivery and stability are controlled by interacting proteins: ABHD6 binds the GluA C-terminus to suppress membrane delivery and currents [PMID:28303090], and α2δ-1 drives K861 ubiquitination and proteasomal degradation of GluA3 to shift spinal AMPAR composition toward Ca2+-permeable homomers during neuropathic pain [PMID:41129242]. In disease, Aβ oligomers trigger PDZ-motif-dependent endocytosis and endolysosomal degradation of GluA3, and GluA3 is required for Aβ-driven synaptic depression and spine loss [PMID:27708157, PMID:39779375]. Distinct gain-of-function and loss-of-function GRIA3 variants alter channel gating and surface expression and cause genetically defined neurodevelopmental encephalopathies with divergent clinical features [PMID:38038360, PMID:34161333, PMID:32369665], and anti-GluA3 autoantibodies delocalize the receptor from synapses, contributing to glutamatergic dysfunction in frontotemporal dementia [PMID:28751743, PMID:31784278].","teleology":[{"year":2010,"claim":"Establishing the intrinsic single-channel behavior of GluA3 was needed to define how this subunit gates; recordings showed homomeric GluA3 opens to three conductance levels with agonist-dependent open probabilities, framing the receptor as a multi-state channel.","evidence":"Single-channel patch-clamp of homomeric GluA3 with agonist series and kinetic modeling","pmids":["20816055"],"confidence":"High","gaps":["Did not address heteromeric GluA2/3 gating","No link to modulation by intracellular signaling"]},{"year":2010,"claim":"To understand subtype- and isoform-selective pharmacology, crystallography of the GluA3 LBD with the modulator PEPA revealed that flop selectivity arises from bidentate hydrogen bonding at N754, mapping a druggable allosteric surface.","evidence":"X-ray crystallography of GluA2 and GluA3 flop LBD-PEPA complexes","pmids":["20199107"],"confidence":"High","gaps":["Static LBD-only structures lack full-receptor context","Functional consequences in native synapses not tested"]},{"year":2010,"claim":"A non-neuronal role was probed by placing GRIA3 in a cancer pathway; it was identified as a CUX1 transcriptional target whose knockdown reduces pancreatic tumor cell proliferation and xenograft growth.","evidence":"RNAi/overexpression, xenograft model, AMPAR antagonist treatment in pancreatic cancer cells","pmids":["20689760"],"confidence":"Medium","gaps":["Mechanism by which AMPAR signaling drives proliferation unclear","Single-context finding outside neural biology"]},{"year":2016,"claim":"The longstanding question of why GluA3 homomers express poorly at the surface was resolved by identifying LBD residues Tyr-454 and Arg-461 that drive nonproductive assembly and aggregation, with GluA2 co-assembly rescuing trafficking.","evidence":"Biochemical fractionation, surface expression assays, and LBD mutagenesis","pmids":["26912664"],"confidence":"High","gaps":["Did not resolve the structural basis of the aggregation-prone conformation","Cellular chaperone/QC machinery not identified"]},{"year":2016,"claim":"Whether GluA3 is required for amyloid-driven synaptic damage was tested genetically; GluA3-deficient neurons and mice were resistant to Aβ-mediated synaptic depression, spine loss, and memory impairment, placing GluA3 downstream of Aβ pathology.","evidence":"GluA3 KO crossed with Aβ-overproducing mice; electrophysiology, spine imaging, behavior","pmids":["27708157"],"confidence":"High","gaps":["Molecular route of Aβ-to-GluA3 coupling not yet defined","Did not distinguish homomeric vs heteromeric GluA3"]},{"year":2017,"claim":"How basal GluA2/3 receptors contribute to plasticity was clarified by showing they sit in a low-conductance state and switch to high conductance via cAMP/PKA/Ras, defining a gating-based, non-trafficking form of potentiation.","evidence":"Hippocampal electrophysiology, cAMP/PKA/Ras pharmacology, GluA3 KO","pmids":["28762944"],"confidence":"High","gaps":["Molecular target of PKA/Ras on the receptor not mapped","Physiological triggers in vivo not fully defined"]},{"year":2017,"claim":"Cerebellar LTP and motor learning were shown to depend on GluA3, not GluA1, via Epac/cAMP-driven changes in open-channel probability, establishing a subunit-specific plasticity mechanism distinct from receptor insertion.","evidence":"GluA1 and GluA3 KO mice, electrophysiology, VOR behavior, cAMP/Epac pharmacology","pmids":["28103481"],"confidence":"High","gaps":["Direct demonstration of conductance switch at PF-PC synapse incomplete","Epac downstream effectors on GluA3 unknown"]},{"year":2017,"claim":"Negative regulators of GluA3 surface delivery were identified; ABHD6 binds GluA C-termini directly and suppresses membrane delivery and currents, with C-terminal deletion abolishing both binding and inhibition.","evidence":"HEK293T expression, electrophysiology, surface biotinylation, pull-down with deletion constructs","pmids":["28303090"],"confidence":"Medium","gaps":["Native neuronal stoichiometry of ABHD6-GluA3 not established","Reciprocal in vivo validation limited"]},{"year":2017,"claim":"At auditory synapses GluA3 was assigned a structural organizing role; it concentrates AMPARs at the center of AN-bushy cell synapses, and its loss randomizes intrasynaptic distribution.","evidence":"Quantitative freeze-fracture replica immunogold labeling in WT and GluA3 KO mice","pmids":["28397107"],"confidence":"High","gaps":["Molecular interactions driving central clustering not identified","Link to physiological signaling speed not addressed here"]},{"year":2017,"claim":"The first evidence that anti-GluA3 autoimmunity is synaptotoxic came from patient CSF reducing GluA3 synaptic localization and causing spine loss with increased Tau, linking GluA3 dysfunction to FTD.","evidence":"Rat hippocampal and hiPSC-derived neurons treated with patient CSF; immunofluorescence and spine counting","pmids":["28751743"],"confidence":"Medium","gaps":["Antibody epitope and binding mode not defined","Causal contribution to human disease not established"]},{"year":2016,"claim":"GluA3 was shown to be required for normal auditory processing and experience-dependent plasticity, with KO causing reduced postsynaptic densities and impaired ABR recovery after earplugging.","evidence":"ABR and electron microscopy in WT vs GluA3 KO mice with monaural earplugging","pmids":["28011083"],"confidence":"Medium","gaps":["Mechanism connecting GluA3 loss to PSD reduction unclear","Activity-dependent regulation only partly characterized"]},{"year":2011,"claim":"Activity-dependent control of GluA3-containing receptor composition at auditory synapses was demonstrated by increased GluA2/3 labeling after conductive hearing loss, implicating GluA3 in homeostatic plasticity.","evidence":"Monaural earplugging in rats with quantitative subunit-specific immunohistochemistry","pmids":["22044924"],"confidence":"Medium","gaps":["Signaling driving subunit switching not identified","Functional consequence at single-synapse level not measured"]},{"year":2017,"claim":"The first GRIA3 disease variant mechanism was defined; pore mutation A653T stabilizes a closed channel and produces altered sleep/activity in knock-in mice, linking GluA3 gating to circadian and arousal phenotypes.","evidence":"In vitro electrophysiology of A653T plus CRISPR knock-in mouse actigraphy","pmids":["29016847"],"confidence":"High","gaps":["Circuit basis of sleep phenotype not mapped","Single-variant scope"]},{"year":2020,"claim":"A loss-of-function disease mechanism was established for the TM4 variant G826D, which reduces agonist responses and surface expression, broadening the variant spectrum.","evidence":"Two-electrode voltage clamp in oocytes and β-lactamase surface reporter in HEK293","pmids":["32369665"],"confidence":"Medium","gaps":["No in vivo model of this variant","Synaptic consequences not tested"]},{"year":2021,"claim":"Gain-of-function variant biology was demonstrated; R660T slows desensitization/deactivation in homomers and heteromers and slows neuronal EPSCs, showing how GOF prolongs glutamatergic signaling.","evidence":"Voltage clamp in oocytes, patch clamp in HEK and neurons, in utero electroporation","pmids":["34161333"],"confidence":"High","gaps":["Behavioral consequence in a mammalian model untested","Structural basis of kinetic slowing not resolved"]},{"year":2022,"claim":"Complete loss-of-function variants were tied to a circuit-level behavioral phenotype; G630R and E787G abolish channel function, and mPFC GluA3 re-expression rescues aggression in KO mice.","evidence":"Patch-clamp of mutants, GluA3 KO with AAV mPFC rescue, aggression assays","pmids":["35697757"],"confidence":"High","gaps":["Human causality limited to small patient cohort","mPFC circuit mechanism only partly defined"]},{"year":2022,"claim":"A partial gain-of-function variant A615V was characterized with kinetic slowing and a Drosophila epistasis model, and clinical seizure/hypertonia response to carbamazepine connected GOF to presynaptic glutamate release.","evidence":"Patch-clamp of mutants, Drosophila genetic epistasis, clinical pharmacology","pmids":["35031858"],"confidence":"Medium","gaps":["Limited replication of Drosophila result","Mammalian validation absent"]},{"year":2022,"claim":"The GluA3 native interactome was resolved using KO-controlled proteomics, showing GluA2/3 receptors preferentially associate with CNIH-2, TARP-γ2, and Noelin1, distinguishing them from GluA1/2 complexes.","evidence":"Affinity purification mass spectrometry from Gria1/Gria3 KO hippocampi with co-IP validation","pmids":["36429079"],"confidence":"Medium","gaps":["Functional role of each interactor on GluA3 not dissected","Single-lab interactome"]},{"year":2023,"claim":"Systematic functional classification of NDD variants established two mechanistic disease classes; 31 of 43 variants altered function as LOF or GOF, and each class mapped onto distinct clinical phenotypes.","evidence":"Electrophysiology of 44 variants in heterologous cells with clinical correlation across patients","pmids":["38038360"],"confidence":"High","gaps":["In vivo phenotype-genotype mechanism not modeled for most variants","Heteromeric context not always tested"]},{"year":2019,"claim":"Anti-GluA3 autoantibodies were linked to functional glutamatergic deficits in FTD, decreasing glutamate release and altering GluA3 and scaffolding protein levels in patient brain with TMS confirmation.","evidence":"Neurochemistry of FTLD-tau brain specimens, TMS, CSF glutamate/serine measurement","pmids":["31784278"],"confidence":"Medium","gaps":["Causal versus correlative role of autoantibodies unresolved","Antibody epitope not mapped"]},{"year":2025,"claim":"The structural basis of GluA3 trafficking control was defined by cryo-EM showing tightly coupled NTD-LBD tiers and an Arg163 stack whose rupture increases synaptic heteromer trafficking, identifying a mammalian-specific checkpoint.","evidence":"Cryo-EM across gating states with mutagenesis and trafficking assays","pmids":["40592473"],"confidence":"High","gaps":["Signaling that engages this checkpoint in vivo unknown","Link to disease variants not directly tested"]},{"year":2025,"claim":"The molecular route of Aβ-driven GluA3 loss was pinned to the PDZ-binding motif; Aβ triggers endocytosis and endolysosomal degradation of GluA3, and a single PDZ-motif mutation renders synapses Aβ-resistant.","evidence":"Imaging endocytosis, PDZ-motif mutagenesis, electrophysiology, APP/PS1 synaptosome proteomics","pmids":["39779375"],"confidence":"High","gaps":["PDZ partner mediating degradation not identified","Therapeutic targeting in vivo not demonstrated"]},{"year":2025,"claim":"A degradation pathway controlling spinal AMPAR composition in pain was defined; α2δ-1 drives K861 ubiquitination and proteasomal degradation of GluA3, and intrathecal Gria3 delivery reverses nerve-injury hypersensitivity.","evidence":"Co-expression, proteasome inhibition, K861 mutagenesis, nerve-injury model with Gria3 gene therapy","pmids":["41129242"],"confidence":"High","gaps":["E3 ligase acting on K861 not identified","Generalizability beyond spinal cord untested"]},{"year":2025,"claim":"Chronic anti-GluA3 IgG exposure was shown to delocalize GluA3 extrasynaptically and remodel dendrites with enhanced NMDA Ca2+ currents and elevated phospho-CREB, detailing downstream synaptic consequences of GluA3 autoimmunity.","evidence":"Primary rat hippocampal neurons with immunofluorescence, dendritic morphology, Ca2+ imaging, phospho-CREB staining","pmids":["39954743"],"confidence":"Medium","gaps":["In vivo relevance to human FTD not established","Antibody mechanism of delocalization not defined"]},{"year":null,"claim":"How the structurally defined Arg163 trafficking checkpoint, signaling-driven conductance switching, and the degradation pathways (PDZ-motif/endolysosomal, ABHD6, α2δ-1/K861) are integrated in vivo to set GluA3 abundance, composition, and conductance state across synapse types remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking structural checkpoint to disease variant classes","E3 ligases and PDZ partners mediating GluA3 degradation unidentified","In vivo coupling of conductance-state switching to specific signaling inputs incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[1,5,15]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,2,5]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[11]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[8,9,11,4]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[1,2,12]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[4,20]}],"complexes":["AMPA receptor (GluA2/3 heteromer)","GluA3 homomer"],"partners":["GRIA2","ABHD6","CNIH2","CACNG2","OLFM1","CACNA2D1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P42263","full_name":"Glutamate receptor 3","aliases":["AMPA-selective glutamate receptor 3","GluR-C","GluR-K3","Glutamate receptor ionotropic, AMPA 3"],"length_aa":894,"mass_kda":101.2,"function":"Ionotropic glutamate receptor that functions as a ligand-gated cation channel, gated by L-glutamate and glutamatergic agonists such as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), quisqualic acid, and kainic acid (By similarity). L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system and plays an important role in fast excitatory synaptic transmission by inducing long-term potentiation (By similarity). Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse upon entry of calcium (PubMed:17989220). The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist (PubMed:17989220). In the presence of CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate (PubMed:21172611)","subcellular_location":"Cell membrane; Postsynaptic cell membrane; Postsynaptic density membrane","url":"https://www.uniprot.org/uniprotkb/P42263/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GRIA3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GRIA3","total_profiled":1310},"omim":[{"mim_id":"620719","title":"NEURODEVELOPMENTAL DISORDER WITH MOTOR ABNORMALITIES, SEIZURES, AND FACIAL DYSMORPHISM; NEDMSF","url":"https://www.omim.org/entry/620719"},{"mim_id":"607204","title":"PUMILIO RNA BINDING FAMILY MEMBER 1; PUM1","url":"https://www.omim.org/entry/607204"},{"mim_id":"602926","title":"SYNTAXIN-BINDING PROTEIN 1; STXBP1","url":"https://www.omim.org/entry/602926"},{"mim_id":"305915","title":"GLUTAMATE RECEPTOR, IONOTROPIC, AMPA 3; GRIA3","url":"https://www.omim.org/entry/305915"},{"mim_id":"300979","title":"CHROMOSOME Xq25 DUPLICATION SYNDROME","url":"https://www.omim.org/entry/300979"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":38.9},{"tissue":"retina","ntpm":15.5}],"url":"https://www.proteinatlas.org/search/GRIA3"},"hgnc":{"alias_symbol":["GluA3","GLURC","MRX94","GluR-3","GluR-C","GluR-K3","iGluR3"],"prev_symbol":["GLUR3"]},"alphafold":{"accession":"P42263","domains":[{"cath_id":"3.40.50.2300","chopping":"32-140_295-369","consensus_level":"high","plddt":89.9505,"start":32,"end":369},{"cath_id":"3.40.50.2300","chopping":"144-271_381-406","consensus_level":"high","plddt":88.1019,"start":144,"end":406},{"cath_id":"3.40.190.10","chopping":"418-527_763-806","consensus_level":"medium","plddt":89.609,"start":418,"end":806},{"cath_id":"3.40.190.10","chopping":"532-537_663-760","consensus_level":"high","plddt":91.8974,"start":532,"end":760},{"cath_id":"1.10.287","chopping":"545-581_601-658_821-854","consensus_level":"high","plddt":84.3741,"start":545,"end":854}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P42263","model_url":"https://alphafold.ebi.ac.uk/files/AF-P42263-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P42263-F1-predicted_aligned_error_v6.png","plddt_mean":83.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GRIA3","jax_strain_url":"https://www.jax.org/strain/search?query=GRIA3"},"sequence":{"accession":"P42263","fasta_url":"https://rest.uniprot.org/uniprotkb/P42263.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P42263/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P42263"}},"corpus_meta":[{"pmid":"27708157","id":"PMC_27708157","title":"Amyloid-β effects on synapses and memory require AMPA receptor subunit GluA3.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27708157","citation_count":113,"is_preprint":false},{"pmid":"16436610","id":"PMC_16436610","title":"Involvement of the AMPA receptor GluR-C subunit in alcohol-seeking behavior and relapse.","date":"2006","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16436610","citation_count":112,"is_preprint":false},{"pmid":"28103481","id":"PMC_28103481","title":"Motor Learning Requires Purkinje Cell Synaptic Potentiation through Activation of AMPA-Receptor Subunit GluA3.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28103481","citation_count":88,"is_preprint":false},{"pmid":"28629431","id":"PMC_28629431","title":"MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28629431","citation_count":77,"is_preprint":false},{"pmid":"10644433","id":"PMC_10644433","title":"Characterization of the human glutamate receptor subunit 3 gene (GRIA3), a candidate for bipolar disorder and nonspecific X-linked mental retardation.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10644433","citation_count":74,"is_preprint":false},{"pmid":"22285418","id":"PMC_22285418","title":"GluA3-deficiency in mice is associated with increased social and aggressive behavior and elevated dopamine in striatum.","date":"2012","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/22285418","citation_count":68,"is_preprint":false},{"pmid":"28762944","id":"PMC_28762944","title":"Synaptic plasticity through activation of GluA3-containing AMPA-receptors.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28762944","citation_count":62,"is_preprint":false},{"pmid":"31498117","id":"PMC_31498117","title":"MicroRNA-330-3p promotes brain metastasis and epithelial-mesenchymal transition via GRIA3 in non-small cell lung cancer.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31498117","citation_count":52,"is_preprint":false},{"pmid":"31784278","id":"PMC_31784278","title":"Anti-GluA3 antibodies in frontotemporal dementia: effects on glutamatergic neurotransmission and synaptic failure.","date":"2019","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/31784278","citation_count":43,"is_preprint":false},{"pmid":"29863014","id":"PMC_29863014","title":"Chaihu-Shugan-San exerts an antidepressive effect by downregulating miR-124 and releasing inhibition of the MAPK14 and Gria3 signaling pathways.","date":"2018","source":"Neural regeneration research","url":"https://pubmed.ncbi.nlm.nih.gov/29863014","citation_count":40,"is_preprint":false},{"pmid":"20689760","id":"PMC_20689760","title":"Glutamate receptor GRIA3--target of CUX1 and mediator of tumor progression in pancreatic cancer.","date":"2010","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20689760","citation_count":39,"is_preprint":false},{"pmid":"34652536","id":"PMC_34652536","title":"Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3.","date":"2021","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34652536","citation_count":39,"is_preprint":false},{"pmid":"23149219","id":"PMC_23149219","title":"Evaluation of hypermethylation and expression pattern of GMR2, GMR5, GMR8, and GRIA3 in patients with schizophrenia.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23149219","citation_count":38,"is_preprint":false},{"pmid":"29016847","id":"PMC_29016847","title":"A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29016847","citation_count":38,"is_preprint":false},{"pmid":"20816055","id":"PMC_20816055","title":"Characterizing single-channel behavior of GluA3 receptors.","date":"2010","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/20816055","citation_count":37,"is_preprint":false},{"pmid":"28751743","id":"PMC_28751743","title":"Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28751743","citation_count":35,"is_preprint":false},{"pmid":"20579352","id":"PMC_20579352","title":"Common variants in the regulative regions of GRIA1 and GRIA3 receptor genes are associated with migraine susceptibility.","date":"2010","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20579352","citation_count":35,"is_preprint":false},{"pmid":"20199107","id":"PMC_20199107","title":"Molecular mechanism of flop selectivity and subsite recognition for an AMPA receptor allosteric modulator: structures of GluA2 and GluA3 in complexes with PEPA.","date":"2010","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20199107","citation_count":34,"is_preprint":false},{"pmid":"19449417","id":"PMC_19449417","title":"Aberrant GRIA3 transcripts with multi-exon duplications in a family with X-linked mental retardation.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19449417","citation_count":34,"is_preprint":false},{"pmid":"32977175","id":"PMC_32977175","title":"GRIA3 missense mutation is cause of an x-linked developmental and epileptic encephalopathy.","date":"2020","source":"Seizure","url":"https://pubmed.ncbi.nlm.nih.gov/32977175","citation_count":29,"is_preprint":false},{"pmid":"18163426","id":"PMC_18163426","title":"Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18163426","citation_count":27,"is_preprint":false},{"pmid":"22044924","id":"PMC_22044924","title":"Monaural conductive hearing loss alters the expression of the GluA3 AMPA and glycine receptor α1 subunits in bushy and fusiform cells of the cochlear nucleus.","date":"2011","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22044924","citation_count":27,"is_preprint":false},{"pmid":"28397107","id":"PMC_28397107","title":"The number and distribution of AMPA receptor channels containing fast kinetic GluA3 and GluA4 subunits at auditory nerve synapses depend on the target cells.","date":"2017","source":"Brain structure & function","url":"https://pubmed.ncbi.nlm.nih.gov/28397107","citation_count":26,"is_preprint":false},{"pmid":"17568425","id":"PMC_17568425","title":"Partial tandem duplication of GRIA3 in a male with mental retardation.","date":"2007","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17568425","citation_count":26,"is_preprint":false},{"pmid":"32051325","id":"PMC_32051325","title":"Role of GluA3 AMPA Receptor Subunits in the Presynaptic and Postsynaptic Maturation of Synaptic Transmission and Plasticity of Endbulb-Bushy Cell Synapses in the Cochlear Nucleus.","date":"2020","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32051325","citation_count":24,"is_preprint":false},{"pmid":"34743951","id":"PMC_34743951","title":"GluA3-containing AMPA receptors: From physiology to synaptic dysfunction in brain disorders.","date":"2021","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/34743951","citation_count":21,"is_preprint":false},{"pmid":"23637084","id":"PMC_23637084","title":"Xq25 duplications encompassing GRIA3 and STAG2 genes in two families convey recognizable X-linked intellectual disability with distinctive facial appearance.","date":"2013","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/23637084","citation_count":21,"is_preprint":false},{"pmid":"38038360","id":"PMC_38038360","title":"Gain-of-function and loss-of-function variants in GRIA3 lead to distinct neurodevelopmental phenotypes.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/38038360","citation_count":20,"is_preprint":false},{"pmid":"34161333","id":"PMC_34161333","title":"X-linked neonatal-onset epileptic encephalopathy associated with a gain-of-function variant p.R660T in GRIA3.","date":"2021","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34161333","citation_count":20,"is_preprint":false},{"pmid":"28011083","id":"PMC_28011083","title":"Impaired auditory processing and altered structure of the endbulb of Held synapse in mice lacking the GluA3 subunit of AMPA receptors.","date":"2016","source":"Hearing research","url":"https://pubmed.ncbi.nlm.nih.gov/28011083","citation_count":20,"is_preprint":false},{"pmid":"36429079","id":"PMC_36429079","title":"Expression and Interaction Proteomics of GluA1- and GluA3-Subunit-Containing AMPARs Reveal Distinct Protein Composition.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36429079","citation_count":18,"is_preprint":false},{"pmid":"35697757","id":"PMC_35697757","title":"Dysfunction of AMPA receptor GluA3 is associated with aggressive behavior in human.","date":"2022","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/35697757","citation_count":17,"is_preprint":false},{"pmid":"32369665","id":"PMC_32369665","title":"The GRIA3 c.2477G > A Variant Causes an Exaggerated Startle Reflex, Chorea, and Multifocal Myoclonus.","date":"2020","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/32369665","citation_count":17,"is_preprint":false},{"pmid":"23772601","id":"PMC_23772601","title":"Association of a GRIA3 gene polymorphism with migraine in an Australian case-control cohort.","date":"2013","source":"Headache","url":"https://pubmed.ncbi.nlm.nih.gov/23772601","citation_count":17,"is_preprint":false},{"pmid":"30528594","id":"PMC_30528594","title":"Druggability Simulations and X-Ray Crystallography Reveal a Ligand-Binding Site in the GluA3 AMPA Receptor N-Terminal Domain.","date":"2018","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/30528594","citation_count":17,"is_preprint":false},{"pmid":"28303090","id":"PMC_28303090","title":"The Inhibitory Effect of α/β-Hydrolase Domain-Containing 6 (ABHD6) on the Surface Targeting of GluA2- and GluA3-Containing AMPA Receptors.","date":"2017","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28303090","citation_count":17,"is_preprint":false},{"pmid":"26800698","id":"PMC_26800698","title":"Case-control study of GRIA1 and GRIA3 gene variants in migraine.","date":"2016","source":"The journal of headache and pain","url":"https://pubmed.ncbi.nlm.nih.gov/26800698","citation_count":15,"is_preprint":false},{"pmid":"21966062","id":"PMC_21966062","title":"Shared genetic background for regulation of mood and sleep: association of GRIA3 with sleep duration in healthy Finnish women.","date":"2011","source":"Sleep","url":"https://pubmed.ncbi.nlm.nih.gov/21966062","citation_count":15,"is_preprint":false},{"pmid":"22124977","id":"PMC_22124977","title":"Exploring the potential role of disease-causing mutation in a gene desert: duplication of noncoding elements 5' of GRIA3 is associated with GRIA3 silencing and X-linked intellectual disability.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/22124977","citation_count":14,"is_preprint":false},{"pmid":"26912664","id":"PMC_26912664","title":"Aggregation Limits Surface Expression of Homomeric GluA3 Receptors.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26912664","citation_count":12,"is_preprint":false},{"pmid":"29338492","id":"PMC_29338492","title":"Genetic variation of GRIA3 gene is associated with vulnerability to methamphetamine dependence and its associated psychosis.","date":"2018","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29338492","citation_count":10,"is_preprint":false},{"pmid":"40592473","id":"PMC_40592473","title":"Architecture, dynamics and biogenesis of GluA3 AMPA glutamate receptors.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/40592473","citation_count":7,"is_preprint":false},{"pmid":"35093607","id":"PMC_35093607","title":"The p.Glu787Lys variant in the GRIA3 gene causes developmental and epileptic encephalopathy mimicking structural epilepsy in a female patient.","date":"2022","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35093607","citation_count":7,"is_preprint":false},{"pmid":"34731330","id":"PMC_34731330","title":"Myoclonic status epilepticus and cerebellar hypoplasia associated with a novel variant in the GRIA3 gene.","date":"2021","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/34731330","citation_count":7,"is_preprint":false},{"pmid":"29316954","id":"PMC_29316954","title":"Correction to: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.","date":"2018","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29316954","citation_count":7,"is_preprint":false},{"pmid":"33092612","id":"PMC_33092612","title":"Retraction Note to: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.","date":"2020","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33092612","citation_count":7,"is_preprint":false},{"pmid":"37626593","id":"PMC_37626593","title":"The Expression of Epac2 and GluA3 in an Alzheimer's Disease Experimental Model and Postmortem Patient Samples.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/37626593","citation_count":6,"is_preprint":false},{"pmid":"35031858","id":"PMC_35031858","title":"Amelioration of a neurodevelopmental disorder by carbamazepine in a case having a gain-of-function GRIA3 variant.","date":"2022","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35031858","citation_count":6,"is_preprint":false},{"pmid":"39779375","id":"PMC_39779375","title":"Amyloid-β-Driven Synaptic Deficits Are Mediated by Synaptic Removal of GluA3-Containing AMPA Receptors.","date":"2025","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/39779375","citation_count":5,"is_preprint":false},{"pmid":"36726007","id":"PMC_36726007","title":"GRIA3 p.Met661Thr variant in a female with developmental epileptic encephalopathy.","date":"2023","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/36726007","citation_count":5,"is_preprint":false},{"pmid":"38142840","id":"PMC_38142840","title":"Novel crosstalk mechanisms between GluA3 and Epac2 in synaptic plasticity and memory in Alzheimer's disease.","date":"2023","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38142840","citation_count":4,"is_preprint":false},{"pmid":"28103474","id":"PMC_28103474","title":"Learning about Synaptic GluA3.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28103474","citation_count":3,"is_preprint":false},{"pmid":"39954743","id":"PMC_39954743","title":"Long-term exposure to anti-GluA3 antibodies triggers functional and structural changes in hippocampal neurons.","date":"2025","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39954743","citation_count":2,"is_preprint":false},{"pmid":"41129242","id":"PMC_41129242","title":"Spinal α2δ-1 induces GluA3 degradation to regulate assembly of calcium-permeable AMPA receptors and pain hypersensitivity.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/41129242","citation_count":2,"is_preprint":false},{"pmid":"31400139","id":"PMC_31400139","title":"[X-linked mental retardation combined with autism caused by a novel hemizygous mutation of GRIA3 gene].","date":"2019","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31400139","citation_count":2,"is_preprint":false},{"pmid":"40930967","id":"PMC_40930967","title":"Mixed functional consequences of the N651D GRIA3 variant: a case of early-onset developmental and epileptic encephalopathy with parkinsonism.","date":"2025","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40930967","citation_count":2,"is_preprint":false},{"pmid":"33269432","id":"PMC_33269432","title":"TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.","date":"2020","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33269432","citation_count":1,"is_preprint":false},{"pmid":"11725645","id":"PMC_11725645","title":"[Linkage analysis and mutation detection of GRIA3 in Smith--Fineman--Myers syndrome].","date":"2001","source":"Yi chuan xue bao = Acta genetica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/11725645","citation_count":1,"is_preprint":false},{"pmid":"20564826","id":"PMC_20564826","title":"[Analyzing GRIA3 gene mutations located in AUNX1 locus in a Chinese pedigree with auditory neuropathy].","date":"2010","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20564826","citation_count":1,"is_preprint":false},{"pmid":"40361628","id":"PMC_40361628","title":"Effects of LMW-GS Allelic Variations at the Glu-A3 Locus on Fresh Wet Noodle and Frozen Cooked Noodle Quality.","date":"2025","source":"Foods (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40361628","citation_count":1,"is_preprint":false},{"pmid":"41462794","id":"PMC_41462794","title":"Non-Convulsive Status Epilepticus and Mild Neurodevelopmental Phenotype in a Female with a Novel p.Thr657Ala Variant in the GRIA3 Gene.","date":"2025","source":"Children (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41462794","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.15.623468","title":"Brain-region-specific changes and dysregulation of activity regulated genes in  <i>Gria3</i>  mutant mice, a genetic animal model of schizophrenia","date":"2024-11-17","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.15.623468","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.11.13.25339504","title":"Trisomy 21 Drives ADARB1 Overexpression and Premature RNA Recoding in the Developing Fetal Brain","date":"2025-11-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.13.25339504","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.01.601494","title":"<i>In Vitro</i>  Generation and Characterization of The Wu Syndrome Model That Causes Mental Retardation in Neural Cell Lines","date":"2024-07-01","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.01.601494","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.26.645496","title":"Meta-analysis of the brain transcriptomes of multiple genetic mouse models of schizophrenia highlights dysregulation in striatum and thalamus","date":"2025-03-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.26.645496","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.20.599978","title":"α/β-Hydrolase domain-containing 6 (ABHD6) accelerates the desensitization and deactivation of TARP γ-2-containing AMPA receptors","date":"2024-06-25","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.20.599978","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34709,"output_tokens":7534,"usd":0.108568,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16789,"output_tokens":6964,"usd":0.129023,"stage2_stop_reason":"end_turn"},"total_usd":0.237591,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2025,\n      \"finding\": \"Cryo-EM structures of Ca2+-permeable GluA3 homomers reveal a unique architecture where the N-terminal domain (NTD) and ligand-binding domain (LBD) tiers are closely coupled throughout gating states. A stacking interaction between two Arg163 residues in the NTD dimer interface traps a unique NTD dimer conformation enabling close NTD-LBD contacts. Rupture of the Arg163 stack alters extracellular region structure/dynamics and increases GluA3 heteromer trafficking to synapses. A mammalian-specific GluA3 trafficking checkpoint determines LBD tier conformational stability.\",\n      \"method\": \"Cryo-electron microscopy with functional validation (mutagenesis, trafficking assays)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structures across gating states combined with mutagenesis and functional trafficking validation in a single rigorous study\",\n      \"pmids\": [\"40592473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GluA2/3-containing AMPARs are in a low-conductance state under basal conditions and contribute little to synaptic currents despite being present at synapses. When intracellular cAMP levels rise (e.g., via β-adrenergic receptor activation), GluA2/3 channels shift to a high-conductance state, producing synaptic potentiation. This cAMP-driven potentiation requires both PKA and the GTPase Ras activation.\",\n      \"method\": \"Electrophysiology in mouse hippocampal neurons (CA1), pharmacological manipulation of cAMP/PKA/Ras pathways, GluA3 knockout comparison\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (electrophysiology, pharmacology, genetic KO) in mouse neurons, replicated across multiple experimental conditions in one rigorous study\",\n      \"pmids\": [\"28762944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cerebellar LTP at the parallel-fiber-to-Purkinje-cell synapse and vestibulo-ocular reflex adaptation depend on GluA3-containing AMPARs, not GluA1-containing AMPARs. This LTP does not require GluA1 AMPAR trafficking but instead requires changes in open-channel probability of GluA3-AMPARs mediated by cAMP signaling and Epac activation.\",\n      \"method\": \"GluA3 and GluA1 knockout mice, electrophysiology, VOR behavioral assay, pharmacological cAMP/Epac manipulation\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with KO mice, electrophysiology, and behavioral assays across multiple orthogonal methods in one study\",\n      \"pmids\": [\"28103481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Aβ oligomer-mediated synaptic depression, spine loss, and blockade of LTP all require the presence of GluA3-containing AMPARs. Hippocampal neurons lacking GluA3 are resistant to Aβ-mediated synaptic depression and spine loss. Aβ-overproducing mice show memory impairment that is absent in GluA3-deficient congenics.\",\n      \"method\": \"GluA3 knockout mice crossed with Aβ-overproducing AD mouse model; electrophysiology, spine imaging, behavioral memory tests\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with KO and transgenic mice, multiple phenotypic readouts (electrophysiology, imaging, behavior), replicated across multiple experimental paradigms\",\n      \"pmids\": [\"27708157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Aβ oligomers trigger endocytosis of GluA3-containing AMPARs and promote their translocation to endolysosomal compartments for degradation. These effects critically depend on the PDZ-binding motif of GluA3; a single point mutation in the GluA3 PDZ-binding motif prevents Aβ-driven endocytosis and renders synapses fully resistant to Aβ. Proteomics of APP/PS1 transgenic mouse synaptosomes confirmed selective early reduction of GluA3.\",\n      \"method\": \"Electrophysiology, AMPAR imaging, site-directed mutagenesis of PDZ-binding motif, live-cell endocytosis assays, synaptosome proteomics from APP/PS1 mice\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis identifying specific motif, imaging of endocytosis/trafficking, proteomics, electrophysiology — multiple orthogonal methods in one study\",\n      \"pmids\": [\"39779375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Single-channel analysis of homomeric GluA3 receptors shows activation by glutamate and the partial agonist fluorowillardiine to the same three open conductance levels but with different open probabilities. Five modes of channel activity were identified, analyzable with a kinetic model of three closed states and two open states per conductance level.\",\n      \"method\": \"Single-channel electrophysiology (patch clamp) with agonist concentration series and X-means algorithm sorting\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous single-channel recordings with multiple agonists and kinetic modeling, single lab\",\n      \"pmids\": [\"20816055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Crystal structures of the flop-selective allosteric modulator PEPA bound to the ligand-binding domains of GluA2 and GluA3 flop isoforms reveal that flop selectivity is conferred by bidentate hydrogen bonding between PEPA and N754 (asparagine in flop; serine in flip). Five subsites on the binding surface contribute to stoichiometry, orientation, and functional outcome of modulator binding.\",\n      \"method\": \"X-ray crystallography of GluA2 and GluA3 LBD-PEPA complexes\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures of both GluA2 and GluA3 with the modulator, specific hydrogen-bonding contacts identified, single lab\",\n      \"pmids\": [\"20199107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Druggability simulations identified a novel ligand-binding site specific to the GluA3 AMPAR N-terminal domain (NTD), arising from its unique conformational flexibility. Crystal structures of GluA3 NTD were trapped in vastly different conformational states, revealing pharmacophoric features not present in other AMPAR subunits.\",\n      \"method\": \"Molecular dynamics druggability simulations plus X-ray crystallography of GluA3 NTD in multiple conformations\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures combined with computational simulations, novel site experimentally confirmed, single lab\",\n      \"pmids\": [\"30528594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Poor surface expression of homomeric GluA3 receptors is caused by nonproductive assembly and aggregation, driven by residues Tyr-454 and Arg-461 in the ligand-binding domain. Co-assembly with GluA2 (but not stargazin) rescues surface expression. GluA3 homomers show a Tyr-454/Arg-461-dependent tendency to aggregate detectable by detergent solubility and density-gradient centrifugation.\",\n      \"method\": \"Biochemical fractionation (nonionic detergent solubility, density gradient centrifugation, native gel electrophoresis), surface expression assays, site-directed mutagenesis of LBD residues\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis identifying specific residues, multiple orthogonal biochemical methods, single lab\",\n      \"pmids\": [\"26912664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ABHD6 suppresses membrane delivery and glutamate-induced currents of GluA2- and GluA3-containing AMPA receptors. Pull-down experiments show ABHD6 binds directly to GluA1-3 via their C-terminal domains; deletion of the GluA C-terminus abolishes both ABHD6 binding and its inhibitory effects on surface expression and currents.\",\n      \"method\": \"HEK293T overexpression, electrophysiology, surface biotinylation assays, pull-down (ABHD6 binding to GluA C-termini), C-terminal deletion constructs\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pulldown and functional assays with deletion constructs, single lab, multiple methods\",\n      \"pmids\": [\"28303090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Interaction proteomics on hippocampi from wildtype vs. Gria3 knockout mice shows that GluA2/3-containing AMPARs preferentially co-purify CNIH-2, TARP-γ2, and Noelin1 (Olfactomedin-1), whereas GluA1/2 receptors preferentially co-purify TARP-γ8, SynDIG4, and CNIH-2. TARP-γ8 and SynDIG4 interact directly and co-assemble into an AMPAR subcomplex at synaptic sites.\",\n      \"method\": \"Affinity purification mass spectrometry (interaction proteomics) from Gria1- or Gria3-KO mouse hippocampi; co-immunoprecipitation and fractionation for TARP-γ8/SynDIG4 interaction\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry interactome with KO controls plus orthogonal co-IP, single lab\",\n      \"pmids\": [\"36429079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In cochlear nucleus, GluA3 subunits are concentrated at the center of auditory nerve-bushy cell (AN-BC) synapses at higher density than GluA4, whereas GluA4 is more abundant at AN-fusiform cell synapses. In GluA3-knockout mice, the central intrasynaptic distribution of AMPARs is lost and gold particles distribute evenly, demonstrating GluA3 specifically organizes the central clustering of AMPARs at AN-BC synapses.\",\n      \"method\": \"Quantitative freeze-fracture replica immunogold labeling (FRIL) of cochlear nucleus synapses in wildtype and GluA3-KO mice\",\n      \"journal\": \"Brain structure & function\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — quantitative ultrastructural immunogold localization with KO controls, rigorous single-synapse resolution, single lab\",\n      \"pmids\": [\"28397107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GluA3 determines the ultrafast kinetics of endbulb-bushy cell synapse glutamatergic currents by promoting insertion of postsynaptic AMPARs containing fast-desensitizing flop subunits. GluA3 is also required for normal presynaptic terminal function, structure, and development: GluA3 KO mice show altered short-term depression, increased vesicle release probability, impaired vesicle replenishment, and reduced readily-releasable pool. GluA3 makes the speed of synaptic depression rate-invariant.\",\n      \"method\": \"Patch-clamp electrophysiology at endbulb synapses in wildtype vs. GluA3 KO mice, electron microscopy of presynaptic terminals\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — electrophysiology with KO genetic model combined with ultrastructural analysis, multiple phenotypic readouts\",\n      \"pmids\": [\"32051325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Deletion of GluA3 leads to impaired auditory signaling (decreased ABR peak amplitudes, increased peak 2 latency, early hearing loss), reduced number and size of postsynaptic densities at AN-BC synapses, and hampered ABR threshold recovery after transient ear plugging, demonstrating GluA3 is required for normal auditory processing and experience-dependent synaptic plasticity.\",\n      \"method\": \"Auditory brainstem responses (ABR) and electron microscopy of AN-BC synapses in wildtype vs. GluA3-KO mice, with transient monaural earplugging paradigm\",\n      \"journal\": \"Hearing research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO genetic model with electrophysiological and ultrastructural readouts, single lab\",\n      \"pmids\": [\"28011083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A missense variant A653T in the GRIA3 ion conduction pore (transmembrane domain) stabilizes the channel in a closed conformation in vitro, opposite to the Lurcher mutation effect. Knock-in of the orthologous mutation in mice by CRISPR-Cas9 causes significantly altered sleep/activity structure with fewer brief bouts and enhanced period lengthening under constant light.\",\n      \"method\": \"In vitro electrophysiology of A653T mutant channels; CRISPR-Cas9 knock-in mouse model with actigraphy/sleep analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro channel characterization plus knock-in mouse phenotyping, two orthogonal experimental approaches, single lab\",\n      \"pmids\": [\"29016847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A gain-of-function variant R660T in GRIA3 causes slower desensitization and deactivation kinetics with substantial non-desensitized steady-state currents in homomeric GluA3 and in GluA2/GluA3 heteromers expressed in HEK cells. In cultured cerebellar granule neurons and hippocampal CA1 neurons expressing R660T, mEPSCs and evoked EPSCs are significantly slower than wildtype.\",\n      \"method\": \"Two-electrode voltage clamp in Xenopus oocytes, patch clamp in HEK cells and primary neurons, in utero electroporation into hippocampal CA1 neurons\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple expression systems and neuronal recordings, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"34161333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Electrophysiological assays of 43 GRIA3 missense variants found in NDD patients showed 31 alter receptor function: some are loss-of-function (reduced currents) and some are gain-of-function (increased/prolonged currents). GOF variants associate with earlier seizure onset, hypertonia, and movement disorders; LOF variants associate with later seizure onset, hypotonia, and sleep disturbances, establishing distinct NDD phenotypes for each functional class.\",\n      \"method\": \"Electrophysiological assays (patch clamp/voltage clamp) of 44 variants expressed in heterologous cells; clinical correlation across 25 patients\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — large-scale systematic in vitro functional testing of 44 variants with clinical correlation, comprehensive coverage across multiple labs\",\n      \"pmids\": [\"38038360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The GRIA3 missense variant Gly826Asp (c.2477G>A) in transmembrane domain 4 causes decreased current response to agonists (kainic acid and glutamate) and reduced cell-surface expression, consistent with a loss-of-function mechanism, as shown by two-electrode voltage clamp in Xenopus oocytes and a β-lactamase reporter assay in HEK293 cells.\",\n      \"method\": \"Two-electrode voltage clamp in Xenopus laevis oocytes; β-lactamase reporter assay in HEK293 cells for surface expression\",\n      \"journal\": \"Movement disorders\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro functional assays with two orthogonal methods, single lab\",\n      \"pmids\": [\"32369665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Two GRIA3 missense variants, G630R and E787G, found in male patients with aggressive behavior, completely abolish GluA3 ion channel function. In GluA3 KO mice, excitatory neurotransmission and neuronal activity in the medial prefrontal cortex (mPFC) are impaired, and viral re-expression of GluA3 in the mPFC alleviates aggressive behavior.\",\n      \"method\": \"Patch-clamp electrophysiology of mutant channels in heterologous cells; GluA3 KO mice with viral rescue (AAV-mediated GluA3 re-expression in mPFC); aggression behavioral assays\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO with viral rescue establishing circuit-level mechanism, electrophysiology of mutant channels, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"35697757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A gain-of-function GRIA3 variant (p.Ala615Val) causes slower desensitization and deactivation kinetics in patch-clamp recordings. In a Drosophila model, expression of a double mutant (Ala615Val + Lurcher, which makes channels leaky) caused developmental defects, while either single variant alone did not, confirming partial GOF. The patient's seizures and hypertonia were ameliorated by carbamazepine, which inhibits glutamate release from presynapses.\",\n      \"method\": \"Patch-clamp recordings of mutant GluA3 in heterologous cells; Drosophila genetic model with epistasis; clinical pharmacological intervention\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro electrophysiology plus Drosophila epistasis, single lab, limited replication\",\n      \"pmids\": [\"35031858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"α2δ-1 (but not α2δ-2 or α2δ-3) co-expression diminishes GluA3 AMPAR currents and protein levels via ubiquitin-proteasome-mediated degradation. K861 at the GluA3 C-terminus is identified as a key ubiquitination site. Nerve injury increases GluA3 ubiquitination and reduces GluA3 and GluA2/GluA3 heteromer levels in spinal cord. Intrathecal Gria3 gene delivery reverses nerve injury-induced nociceptive hypersensitivity and restores GluA2/GluA3 heteromers.\",\n      \"method\": \"Co-expression in heterologous cells, proteasome inhibition, ubiquitination assays, site-directed mutagenesis of K861, nerve injury mouse model with intrathecal Gria3 gene delivery, electrophysiology\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis identifying ubiquitination site, proteasome inhibition, in vivo nerve injury model with gene therapy rescue, multiple orthogonal methods\",\n      \"pmids\": [\"41129242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GRIA3 is a downstream transcriptional target of CUX1 in pancreatic cancer cells. Knockdown of GRIA3 reduces proliferation and migration and enhances apoptosis; overexpression has the opposite effects. GRIA3 knockdown reduces xenograft tumor growth in vivo. AMPAR antagonists (GYKI52466, SYM2206) decrease pancreatic cancer cell survival.\",\n      \"method\": \"RNAi loss-of-function screen, GRIA3 overexpression/knockdown in vitro, xenograft mouse model, AMPAR antagonist treatment\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi and overexpression with in vivo xenograft validation, single lab, pathway placement as CUX1 downstream target\",\n      \"pmids\": [\"20689760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Anti-GluA3 autoantibodies in FTD patients decrease glutamate release and alter levels of GluA3-containing AMPAR, accompanied by changes in scaffolding proteins involved in receptor synaptic retention/internalization, as shown in FTD patient brain specimens and confirmed by TMS measures of glutamatergic neurotransmission.\",\n      \"method\": \"Molecular/neurochemical analyses on patient brain specimens (FTLD-tau neuropathology); transcranial magnetic stimulation; CSF glutamate/serine measurements\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient tissue neurochemistry with TMS functional validation, single lab, multiple methods\",\n      \"pmids\": [\"31784278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CSF containing anti-GluA3 antibodies from FTD patients decreases GluA3 subunit synaptic localization of AMPARs and causes loss of dendritic spines in rat hippocampal primary cultures and hiPSC-derived neurons. Reduced GluA3 in the postsynaptic fraction is accompanied by increased neuronal Tau levels.\",\n      \"method\": \"Rat hippocampal primary neuronal cultures and hiPSC-derived neurons incubated with patient CSF; immunofluorescence for GluA3 synaptic localization; dendritic spine counting\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based functional antibody experiments with two neuronal models, single lab\",\n      \"pmids\": [\"28751743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Long-term exposure to human anti-GluA3 IgGs causes delocalization of GluA3-containing AMPARs to extrasynaptic sites, dendritic arbor reorganization, increased dendritic spine number with altered morphology, enhancement of NMDA receptor-mediated postsynaptic Ca2+ currents, and increased nuclear phospho-CREB levels in primary rat hippocampal neurons.\",\n      \"method\": \"Primary rat hippocampal neurons, immunofluorescence for GluA3 localization, dendritic morphology analysis, Ca2+ imaging, phospho-CREB immunostaining\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based functional antibody experiments with multiple readouts, single lab\",\n      \"pmids\": [\"39954743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"After 7 days of monaural conductive hearing loss (earplugging), immunolabeling for GluA2/3 (but not GluA2 alone) increases on bushy cells and fusiform cells of both ipsilateral and contralateral cochlear nuclei, while GlyRα1 is downregulated in the same cells, indicating activity-dependent regulation of GluA3-containing AMPAR composition at auditory synapses.\",\n      \"method\": \"Monaural earplugging in rats, quantitative immunohistochemistry and biochemistry with subunit-specific antibodies\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative IHC with subunit-selective antibodies and functional hearing manipulation, single lab\",\n      \"pmids\": [\"22044924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss-of-function of Gria3 in mice profoundly alters synapse protein composition, and transcriptomic analysis shows activity-regulated genes are downregulated in cortical regions while immune/glia-related pathways show brain-region-specific changes, distinct from Grin2a mutant mice despite both encoding glutamate receptor subunits associated with schizophrenia risk.\",\n      \"method\": \"Gria3 protein-truncating knock-in mouse model; transcriptomics (RNA-seq); synaptosome proteomics\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomics and proteomics from genetic mouse model, preprint not peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ABHD6 accelerates the deactivation and desensitization of GluA2(R)/GluA3(R) heteromeric receptors in the presence of TARP γ-2 (but not in its absence), as shown by ultra-fast glutamate application and outside-out patch recordings.\",\n      \"method\": \"Ultra-fast agonist application, outside-out patch recordings in HEK cells expressing GluA2/GluA3 heteromers with/without TARP γ-2 and ABHD6; ABHD6-KO neurons\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro kinetics recordings with KO neurons, preprint not peer-reviewed, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"GluA3 (GRIA3) is an AMPA-type glutamate receptor subunit that assembles primarily as GluA2/3 heteromers at cortical/hippocampal synapses and as Ca2+-permeable GluA3 homomers at sensory (auditory) synapses; cryo-EM structures reveal a unique NTD-LBD coupled architecture stabilized by an Arg163 stacking interaction that controls trafficking and gating. Under basal conditions GluA2/3 receptors are in a low-conductance state, but cAMP/PKA/Ras/Epac signaling shifts them to high conductance, enabling a distinct form of synaptic potentiation underlying hippocampal and cerebellar motor learning. Aβ oligomers drive endocytosis and lysosomal degradation of GluA3 via its PDZ-binding motif, causing synaptic depression; ABHD6 binds GluA3 C-termini to inhibit surface delivery; and α2δ-1 promotes K861-ubiquitination and proteasomal degradation of GluA3 to shift spinal AMPAR composition toward Ca2+-permeable homotetramers during neuropathic pain. Loss-of-function and gain-of-function GRIA3 variants each produce distinct neurodevelopmental encephalopathy phenotypes, and autoantibodies against GluA3 delocalize the receptor from synapses causing glutamatergic dysfunction in frontotemporal dementia.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GRIA3 encodes GluA3, an AMPA-type glutamate receptor subunit that mediates fast excitatory synaptic transmission and assembles into both Ca2+-permeable homomers and GluA2/3 heteromers at central and sensory synapses [#1, #11]. Its extracellular architecture is distinctive: cryo-EM of Ca2+-permeable GluA3 homomers reveals tightly coupled NTD and LBD tiers stabilized by an Arg163 stacking interaction whose rupture remodels the extracellular region and increases heteromer trafficking to synapses, defining a mammalian-specific trafficking checkpoint [#0], while the NTD adopts a uniquely flexible set of conformations [#7]. GluA3 homomers traffic poorly because Tyr-454/Arg-461 in the LBD drive nonproductive assembly and aggregation, a defect rescued by co-assembly with GluA2 [#8]. Functionally, GluA2/3 receptors rest in a low-conductance state and convert to high conductance through cAMP/PKA/Ras and Epac signaling, generating a gating-based form of potentiation that underlies hippocampal and cerebellar parallel-fiber LTP and vestibulo-ocular reflex adaptation independently of GluA1 trafficking [#1, #2]. At auditory nerve-bushy cell synapses GluA3 organizes central AMPAR clustering, promotes fast-desensitizing flop-containing receptors that confer ultrafast, rate-invariant kinetics, and is required for normal presynaptic function and auditory processing [#11, #12, #13]. GluA3 surface delivery and stability are controlled by interacting proteins: ABHD6 binds the GluA C-terminus to suppress membrane delivery and currents [#9], and \\u03b12\\u03b4-1 drives K861 ubiquitination and proteasomal degradation of GluA3 to shift spinal AMPAR composition toward Ca2+-permeable homomers during neuropathic pain [#20]. In disease, A\\u03b2 oligomers trigger PDZ-motif-dependent endocytosis and endolysosomal degradation of GluA3, and GluA3 is required for A\\u03b2-driven synaptic depression and spine loss [#3, #4]. Distinct gain-of-function and loss-of-function GRIA3 variants alter channel gating and surface expression and cause genetically defined neurodevelopmental encephalopathies with divergent clinical features [#16, #15, #17], and anti-GluA3 autoantibodies delocalize the receptor from synapses, contributing to glutamatergic dysfunction in frontotemporal dementia [#23, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Establishing the intrinsic single-channel behavior of GluA3 was needed to define how this subunit gates; recordings showed homomeric GluA3 opens to three conductance levels with agonist-dependent open probabilities, framing the receptor as a multi-state channel.\",\n      \"evidence\": \"Single-channel patch-clamp of homomeric GluA3 with agonist series and kinetic modeling\",\n      \"pmids\": [\"20816055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address heteromeric GluA2/3 gating\", \"No link to modulation by intracellular signaling\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"To understand subtype- and isoform-selective pharmacology, crystallography of the GluA3 LBD with the modulator PEPA revealed that flop selectivity arises from bidentate hydrogen bonding at N754, mapping a druggable allosteric surface.\",\n      \"evidence\": \"X-ray crystallography of GluA2 and GluA3 flop LBD-PEPA complexes\",\n      \"pmids\": [\"20199107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Static LBD-only structures lack full-receptor context\", \"Functional consequences in native synapses not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"A non-neuronal role was probed by placing GRIA3 in a cancer pathway; it was identified as a CUX1 transcriptional target whose knockdown reduces pancreatic tumor cell proliferation and xenograft growth.\",\n      \"evidence\": \"RNAi/overexpression, xenograft model, AMPAR antagonist treatment in pancreatic cancer cells\",\n      \"pmids\": [\"20689760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which AMPAR signaling drives proliferation unclear\", \"Single-context finding outside neural biology\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The longstanding question of why GluA3 homomers express poorly at the surface was resolved by identifying LBD residues Tyr-454 and Arg-461 that drive nonproductive assembly and aggregation, with GluA2 co-assembly rescuing trafficking.\",\n      \"evidence\": \"Biochemical fractionation, surface expression assays, and LBD mutagenesis\",\n      \"pmids\": [\"26912664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural basis of the aggregation-prone conformation\", \"Cellular chaperone/QC machinery not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Whether GluA3 is required for amyloid-driven synaptic damage was tested genetically; GluA3-deficient neurons and mice were resistant to A\\u03b2-mediated synaptic depression, spine loss, and memory impairment, placing GluA3 downstream of A\\u03b2 pathology.\",\n      \"evidence\": \"GluA3 KO crossed with A\\u03b2-overproducing mice; electrophysiology, spine imaging, behavior\",\n      \"pmids\": [\"27708157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular route of A\\u03b2-to-GluA3 coupling not yet defined\", \"Did not distinguish homomeric vs heteromeric GluA3\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"How basal GluA2/3 receptors contribute to plasticity was clarified by showing they sit in a low-conductance state and switch to high conductance via cAMP/PKA/Ras, defining a gating-based, non-trafficking form of potentiation.\",\n      \"evidence\": \"Hippocampal electrophysiology, cAMP/PKA/Ras pharmacology, GluA3 KO\",\n      \"pmids\": [\"28762944\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of PKA/Ras on the receptor not mapped\", \"Physiological triggers in vivo not fully defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Cerebellar LTP and motor learning were shown to depend on GluA3, not GluA1, via Epac/cAMP-driven changes in open-channel probability, establishing a subunit-specific plasticity mechanism distinct from receptor insertion.\",\n      \"evidence\": \"GluA1 and GluA3 KO mice, electrophysiology, VOR behavior, cAMP/Epac pharmacology\",\n      \"pmids\": [\"28103481\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct demonstration of conductance switch at PF-PC synapse incomplete\", \"Epac downstream effectors on GluA3 unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Negative regulators of GluA3 surface delivery were identified; ABHD6 binds GluA C-termini directly and suppresses membrane delivery and currents, with C-terminal deletion abolishing both binding and inhibition.\",\n      \"evidence\": \"HEK293T expression, electrophysiology, surface biotinylation, pull-down with deletion constructs\",\n      \"pmids\": [\"28303090\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Native neuronal stoichiometry of ABHD6-GluA3 not established\", \"Reciprocal in vivo validation limited\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"At auditory synapses GluA3 was assigned a structural organizing role; it concentrates AMPARs at the center of AN-bushy cell synapses, and its loss randomizes intrasynaptic distribution.\",\n      \"evidence\": \"Quantitative freeze-fracture replica immunogold labeling in WT and GluA3 KO mice\",\n      \"pmids\": [\"28397107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular interactions driving central clustering not identified\", \"Link to physiological signaling speed not addressed here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The first evidence that anti-GluA3 autoimmunity is synaptotoxic came from patient CSF reducing GluA3 synaptic localization and causing spine loss with increased Tau, linking GluA3 dysfunction to FTD.\",\n      \"evidence\": \"Rat hippocampal and hiPSC-derived neurons treated with patient CSF; immunofluorescence and spine counting\",\n      \"pmids\": [\"28751743\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antibody epitope and binding mode not defined\", \"Causal contribution to human disease not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"GluA3 was shown to be required for normal auditory processing and experience-dependent plasticity, with KO causing reduced postsynaptic densities and impaired ABR recovery after earplugging.\",\n      \"evidence\": \"ABR and electron microscopy in WT vs GluA3 KO mice with monaural earplugging\",\n      \"pmids\": [\"28011083\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting GluA3 loss to PSD reduction unclear\", \"Activity-dependent regulation only partly characterized\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Activity-dependent control of GluA3-containing receptor composition at auditory synapses was demonstrated by increased GluA2/3 labeling after conductive hearing loss, implicating GluA3 in homeostatic plasticity.\",\n      \"evidence\": \"Monaural earplugging in rats with quantitative subunit-specific immunohistochemistry\",\n      \"pmids\": [\"22044924\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling driving subunit switching not identified\", \"Functional consequence at single-synapse level not measured\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The first GRIA3 disease variant mechanism was defined; pore mutation A653T stabilizes a closed channel and produces altered sleep/activity in knock-in mice, linking GluA3 gating to circadian and arousal phenotypes.\",\n      \"evidence\": \"In vitro electrophysiology of A653T plus CRISPR knock-in mouse actigraphy\",\n      \"pmids\": [\"29016847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Circuit basis of sleep phenotype not mapped\", \"Single-variant scope\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A loss-of-function disease mechanism was established for the TM4 variant G826D, which reduces agonist responses and surface expression, broadening the variant spectrum.\",\n      \"evidence\": \"Two-electrode voltage clamp in oocytes and \\u03b2-lactamase surface reporter in HEK293\",\n      \"pmids\": [\"32369665\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo model of this variant\", \"Synaptic consequences not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Gain-of-function variant biology was demonstrated; R660T slows desensitization/deactivation in homomers and heteromers and slows neuronal EPSCs, showing how GOF prolongs glutamatergic signaling.\",\n      \"evidence\": \"Voltage clamp in oocytes, patch clamp in HEK and neurons, in utero electroporation\",\n      \"pmids\": [\"34161333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Behavioral consequence in a mammalian model untested\", \"Structural basis of kinetic slowing not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Complete loss-of-function variants were tied to a circuit-level behavioral phenotype; G630R and E787G abolish channel function, and mPFC GluA3 re-expression rescues aggression in KO mice.\",\n      \"evidence\": \"Patch-clamp of mutants, GluA3 KO with AAV mPFC rescue, aggression assays\",\n      \"pmids\": [\"35697757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human causality limited to small patient cohort\", \"mPFC circuit mechanism only partly defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A partial gain-of-function variant A615V was characterized with kinetic slowing and a Drosophila epistasis model, and clinical seizure/hypertonia response to carbamazepine connected GOF to presynaptic glutamate release.\",\n      \"evidence\": \"Patch-clamp of mutants, Drosophila genetic epistasis, clinical pharmacology\",\n      \"pmids\": [\"35031858\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Limited replication of Drosophila result\", \"Mammalian validation absent\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The GluA3 native interactome was resolved using KO-controlled proteomics, showing GluA2/3 receptors preferentially associate with CNIH-2, TARP-\\u03b32, and Noelin1, distinguishing them from GluA1/2 complexes.\",\n      \"evidence\": \"Affinity purification mass spectrometry from Gria1/Gria3 KO hippocampi with co-IP validation\",\n      \"pmids\": [\"36429079\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of each interactor on GluA3 not dissected\", \"Single-lab interactome\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Systematic functional classification of NDD variants established two mechanistic disease classes; 31 of 43 variants altered function as LOF or GOF, and each class mapped onto distinct clinical phenotypes.\",\n      \"evidence\": \"Electrophysiology of 44 variants in heterologous cells with clinical correlation across patients\",\n      \"pmids\": [\"38038360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo phenotype-genotype mechanism not modeled for most variants\", \"Heteromeric context not always tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Anti-GluA3 autoantibodies were linked to functional glutamatergic deficits in FTD, decreasing glutamate release and altering GluA3 and scaffolding protein levels in patient brain with TMS confirmation.\",\n      \"evidence\": \"Neurochemistry of FTLD-tau brain specimens, TMS, CSF glutamate/serine measurement\",\n      \"pmids\": [\"31784278\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal versus correlative role of autoantibodies unresolved\", \"Antibody epitope not mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The structural basis of GluA3 trafficking control was defined by cryo-EM showing tightly coupled NTD-LBD tiers and an Arg163 stack whose rupture increases synaptic heteromer trafficking, identifying a mammalian-specific checkpoint.\",\n      \"evidence\": \"Cryo-EM across gating states with mutagenesis and trafficking assays\",\n      \"pmids\": [\"40592473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling that engages this checkpoint in vivo unknown\", \"Link to disease variants not directly tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The molecular route of A\\u03b2-driven GluA3 loss was pinned to the PDZ-binding motif; A\\u03b2 triggers endocytosis and endolysosomal degradation of GluA3, and a single PDZ-motif mutation renders synapses A\\u03b2-resistant.\",\n      \"evidence\": \"Imaging endocytosis, PDZ-motif mutagenesis, electrophysiology, APP/PS1 synaptosome proteomics\",\n      \"pmids\": [\"39779375\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PDZ partner mediating degradation not identified\", \"Therapeutic targeting in vivo not demonstrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A degradation pathway controlling spinal AMPAR composition in pain was defined; \\u03b12\\u03b4-1 drives K861 ubiquitination and proteasomal degradation of GluA3, and intrathecal Gria3 delivery reverses nerve-injury hypersensitivity.\",\n      \"evidence\": \"Co-expression, proteasome inhibition, K861 mutagenesis, nerve-injury model with Gria3 gene therapy\",\n      \"pmids\": [\"41129242\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase acting on K861 not identified\", \"Generalizability beyond spinal cord untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Chronic anti-GluA3 IgG exposure was shown to delocalize GluA3 extrasynaptically and remodel dendrites with enhanced NMDA Ca2+ currents and elevated phospho-CREB, detailing downstream synaptic consequences of GluA3 autoimmunity.\",\n      \"evidence\": \"Primary rat hippocampal neurons with immunofluorescence, dendritic morphology, Ca2+ imaging, phospho-CREB staining\",\n      \"pmids\": [\"39954743\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance to human FTD not established\", \"Antibody mechanism of delocalization not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the structurally defined Arg163 trafficking checkpoint, signaling-driven conductance switching, and the degradation pathways (PDZ-motif/endolysosomal, ABHD6, \\u03b12\\u03b4-1/K861) are integrated in vivo to set GluA3 abundance, composition, and conductance state across synapse types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking structural checkpoint to disease variant classes\", \"E3 ligases and PDZ partners mediating GluA3 degradation unidentified\", \"In vivo coupling of conductance-state switching to specific signaling inputs incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [1, 5, 15]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 5]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [8, 9, 11, 4]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [1, 2, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [4, 20]}\n    ],\n    \"complexes\": [\"AMPA receptor (GluA2/3 heteromer)\", \"GluA3 homomer\"],\n    \"partners\": [\"GRIA2\", \"ABHD6\", \"CNIH2\", \"CACNG2\", \"OLFM1\", \"CACNA2D1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}